Spectranetics extends laser to peripheral use:
This article was originally published in Clinica
Spectranetics plans to begin trials of its minimally-invasive laser for treating blocked arteries in the legs. The FDA told the company it could begin a ten-centre trial of the treatment, called peripheral excimer laser angioplasty, if it used a revised protocol based on the trials it undertook to gain approval in Europe. The treatment uses fibre optics to deliver short bursts of laser energy to dissolve blockages. Spectranetics, based in Colorado Springs, Colorado, already markets the CVX-300 excimer laser for cardiac procedures.